Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

09-20-2019 | Heart failure | Video | Article

Researcher comment: The DEFINE-HF trial results

print
PRINT
insite
SEARCH

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

Receive weekly updates on the diabetes news that matters to you

Register for the e-alert!


External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the interview transcript

Back to the EASD 2019 conference hub

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content

09-16-2019 | Heart failure | News

DEFINE-HF: Further support for add-on dapagliflozin as a treatment option for heart failure

09-19-2019 | Heart failure | Video | Article

Researcher comment: The DAPA-HF trial results

09-19-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trial results

09-02-2019 | Heart failure | Highlight | News

Dapagliflozin ‘offers a new approach’ for treating heart failure
Image Credits